Stroke momentum Silver Creek's Phase II results for scp776 in acute ischemic stroke and coverage at the World Stroke Congress indicate meaningful clinical momentum and a compelling case for strategic partnerships, licensing, or co-development deals with neurology-focused pharma and biotech players, as well as potential collaboration with CROs and contract manufacturers to advance toward a pivotal trial.

Leadership transition The departure of President and CEO Dabbagh in June 2026 creates a leadership transition that can open doors for new business development approaches. This period offers an opportunity to present a clear, milestone-driven partnership plan to any evolving executive team and align incentives around rapid value realization.

Funding readiness With modest revenue and roughly nine million in funding, Silver Creek may seek external capital to advance late stage development. This creates a strong case for milestone-based co development or licensing deals that unlock capital, reduce dilution, and maintain momentum toward Phase III readiness.

Indication expansion The focus on growth factor based therapeutics for damaged tissues, led by scp776 in stroke, suggests potential for cross indication partnerships across additional tissue injury applications, enabling broader licensing opportunities with pharma and contract development partners.

Global access South San Francisco location and recent World Stroke Congress participation signal access to a broad ecosystem of CROs, clinical experts, and investors. A business development approach can target global regulatory alignment, manufacturing scale partners, and regional licensing deals to accelerate market entry.